Despite major advances in the treatment of cardiac diseases, there is still a great need for drugs capable of counteracting the deterioration of cardiac muscle function in congestive heart failure. The role of misfolded protein accumulation as a causal event in the physiopathology of common cardiac diseases is an important emerging concept. Indeed, diverse stress conditions, including mechanical stretching and oxidative stress, can induce misfolded protein accumulation, causing cardiomyocyte death. Cells react to these stress conditions by activating molecular chaperones, a class of proteins that represents an endogenous salvage machinery, essential for rescuing physiological cell functions and sustaining cell survival. Chaperones, also known as heat shock proteins (Hsps), prevent accumulation of damaged proteins by promoting either their refolding or degradation via the proteasome or the autophagosome systems. In addition, molecular chaperones play a key role in intracellular signalling by controlling conformational changes required for activation/deactivation of signalling proteins, and their assembly in specific signalosome complexes. The key role of molecular chaperones in heart function is highlighted by the fact that a number of genetic mutations in chaperone proteins result in different forms of cardiomyopathies. Moreover, a considerable amount of experimental evidence indicates that increasing expression of chaperone proteins leads to an important cardio-protective role in ischaemia/reperfusion injury, heart failure, and arrhythmia, implicating these molecules as potential innovative therapeutic agents.
Introduction
The continuous contractile and metabolic activity of cardiomyocytes requires stringent control of synthesis, folding, and turnover of proteins, a process known as proteostasis, in sarcomeres and organelles such as the endoplasmic reticulum (ER) and the mitochondria. However, several pathological conditions, including mechanical and oxidative stress, shifts in pH and temperature, as well as genetic mutations, can unbalance the critical equilibrium of proteostasis inducing accumulation of misfolded proteins. Insoluble aggregates of misfolded proteins can then form which are highly toxic for the cells, causing cell death and leading to cardiac disease such as dilated cardiomyopathy, arrhythmia, and heart failure. 1 Molecular chaperones are a class of proteins devoted to regulating protein folding and maintaining the correct balance between synthesis and degradation. 2 In response to stress conditions, cardiomyocytes increase chaperone expression and activity as a salvage mechanism in order to manage the emergency conditions. Here, we introduce the major chaperone molecules relevant for heart pathophysiology, and discuss their role in regulating protein folding and degradation. We then discuss the involvement of chaperones in important cardiac stress conditions such as ischaemia/reperfusion (I/R) injury, long-term maladaptive remodelling, and arrhythmia. Finally, we address the issue of how chaperones can be exploited as potential therapeutic molecules.
Molecular chaperone function in protein folding and degradation
The chaperone machinery consists of a large number of proteins that often work in a co-operation network. 2, 3 For the purpose of the discussion, we will use a simplified classification of three groups: the general chaperones Hsp90 and Hsp70; the small chaperones (sHsps); and the ER chaperones (Table 1) . Firstly, we describe the major features of these three classes and we then discuss their role in protein quality control, in regulating signalling pathways, and in buffering genetic mutations.
General chaperones
Hsp90 and Hsp70 are the best-known chaperones, and their co-ordinated action controls the folding of most structural and signalling proteins. These chaperones recognize hydrophobic amino acid sidechains exposed by misfolded proteins, and promote their folding by repeated cycles of ATP hydrolysis. The function of Hsp90 and Hsp70 is tightly controlled by accessory proteins known as 'co-chaperones', a class of molecules that regulates the specificity and dynamics of a chaperone reaction, by recognizing specific target proteins and by regulating ATP binding and hydrolysis. 55 Co-chaperones also participate in the Associates with immature HERG potassium channels and is required for efficient maturation in the endoplasmic reticulum and surface expression 5, 6 Hsp70 Protein folding Ubiquitination of misfolded proteins Intracellular signalling
Expression is rapidly induced after ischaemia. Protective effects of Hsp70 have been demonstrated in isolated adult cardiomyocytes and in transgenic hearts 7 -11 Associates with immature HERG potassium channels and is required for efficient maturation in the endoplasmic reticulum and surface expression 5, 6 Hsp40/Dnaja3 14, 15 Mutated in sporadic dilated cardiomyopathies 16 -23 Small Overexpression reduces oxidative stress, decreases infarct size and apoptosis. Null mice show decreased contractility recovery after I/R, with increased necrosis and apoptosis 26, 27, 146 Overexpression attenuates heart hypertrophy after pressure overload, as well as cardiomyocyte hypertrophy in response to neurohumoral stimuli in vitro. Null mice show an accelerated development of heart failure after pressure overload 28 Missense mutations cause desmin-related cardiomyopathy 29 -31 HspB6/Hsp20 Survival signalling: Akt/Bad/ caspase3; ASK1-JNK/ p38 Ca2+ cycling: PP1/ Phospholamban/ SERCA2
Forced expression of HspB6 reduces infarct size, apoptosis, and improves cardiac contractility 32 -35 Overexpression reduces hypertrophy, fibrosis, and apoptosis after chronic isoproterenol infusion or doxorubicin exposure 36, 37 Protective function in an in vitro model of atrial fibrillation 44, 45 Four genetic variations were reported in dilated and hypertrophic cardiomyopathies, but their association with the disease is uncertain 46, 47 Endoplasmic reticulum chaperones and stress response proteins
Grp78
Protein folding Silencing of Grp78 attenuates resistance to ischaemia 48, 49 Increased expression in heart failure patients 50 Activation leads to left ventricle protection upon pressure overload 54 decision towards degradation of misfolded proteins via proteasome or autophagosome pathways, 55, 56 as discussed below in Section 2.4. The current model of chaperone machinery function is schematized in Figure 1 . Firstly, Hsp70 binds to a substrate, known as the 'client' protein, assisted by its co-chaperone Hsp40. An additional co-chaperone, Hop, then promotes the transfer of the client to Hsp90 that, by subsequent cycles of ATP hydrolysis, facilitates conformational changes of the client. This mechanism involves additional co-chaperones, such as p23 and prolylisomerase, capable of regulating Hsp90 ATPase activity and protein folding. 57 ATPase activity is absolutely required for modification of the client protein conformation, as demonstrated by a lack of chaperone function in Hsp90 ATPasedeficient mutants, and by the ability of specific Hsp90 pharmacological ATPase inhibitors, such as geldenamycin, to completely blunt Hsp90 chaperone activity. 58 
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Small chaperones
The family of sHsps or HspB consists of 11 members, characterized by an alpha-crystallin domain which allows homo-and hetero-oligomerization and formation of large supramolecular complexes, likely influencing their chaperone activity. 59, 60 This polymerization process can be regulated by transient phosphorylation in response to stress. 59 sHsps are devoid of ATPase activity and are able to prevent misfolded protein aggregation and regulate intracellular signalling, in some instances in co-operation with Hsp70 and Hsp90. 61, 62 Even though not all known small Hsps have been characterized for their involvement in heart function, the cardioprotective impact of several sHsps is supported by many in vitro and in vivo experimental studies ( Table 1 ).
ER chaperones
The ER of cardiomyocytes consists of distinct portions. A vesicular network localized mainly in the perinuclear region is involved in protein synthesis, whereas a network of membrane vesicles organized around myofibrils and t-tubules, known as the sarcoplasmic reticulum (SR) typically controls excitation-contraction coupling via calcium cycling. The two networks are functionally interconnected to each other and for the purposes of this review we will consider them as a single unit and refer them as the ER. Hypoxia, pressure overload, and drug-induced insults result in activation of a sophisticated chaperone machinery required for maintaining the correct balance between Molecular chaperone networks for treating heart disease protein folding and degradation in the ER. 63, 64 The ER chaperone machinery includes calnexin and calreticulin that control Ca 2+ homoeostasis; the chaperone proteins BiP/Grp78 and Grp94; the protein disulphide isomerase (PDI); and the thiol oxidoreductase ERp57 that assist protein folding and catalyse disulphide bond formation. These molecular chaperones act in concert with three ER membrane complexes, namely PERK, IRE1a, and ATF6, responsible for the activation of the ER stress response, a signalling pathway that senses the accumulation of unfolded proteins and rebalances protein homoeostasis by increasing expression of ER-resident chaperones, inhibiting protein synthesis and activating misfolded protein degradation. 52, 63, 65 Under non-stressed conditions, PERK, IRE1a, and ATF6 bind to the BiP/Grp78 chaperone in the ER lumen, which inhibits their function. Upon ER stress, BiP/Grp78 binds to the misfolded proteins in the ER lumen, dissociating from PERK, IRE1, and ATF6, resulting in their activation ( Figure 2) . PERK is a kinase that attenuates protein synthesis by phosphorylating the eukaryotic initiation factor 2a in the cytoplasm. 52, 63, 65 IRE1 contains an endo-ribonuclease domain in its cytoplasmic region that generates a spliced XBP1 mRNA encoding a potent transcription factor, which activates the expression of ER stress response genes. XBP1 up-regulates genes involved in ubiquitin-dependent protein degradation, promoting the removal of misfolded proteins via the proteasome machinery 52, 63, 65 ( Figure 2) . The third component, ATF6, translocates to the Golgi upon activation, and undergoes cleavage by specific proteases, yielding a soluble cytoplasmic transcription factor (N-ATF6) that enters the nucleus and induces further transcription of ER stress response Figure 2 Endoplasmic reticulum stress response machinery. The endoplasmic reticulum-specific chaperone protein BiP/Grp78 binds to proteins in the lumen of the endoplasmic reticulum, assisting their folding. Bip/Grp78 also binds to the luminal domain of the membrane proteins PERK, IRE1a, and ATF6, inhibiting their function and catalytic activities. During endoplasmic reticulum stress conditions that cause protein misfolding, BiP/Grp78 preferentially binds to the misfolded proteins that have accumulated in the endoplasmic reticulum lumen, dissociating from PERK, IRE1, and ATF6, facilitating their activation. PERK is a kinase, which leads to attenuation of protein synthesis by phosphorylating the eukaryotic initiation factor 2a (eIF2a) in the cytoplasm. IRE1a contains an endo-ribonuclease domain in its cytoplasmic region that generates a spliced XBP1 mRNA encoding a potent transcription factor, which activates expression of endoplasmic reticulum stress response genes. ATF6, upon activation, translocates to the Golgi and undergoes cleavage by specific proteases, S1P and S2P, yielding a soluble cytoplasmic transcription factor, N-ATF6, that enters the nucleus and induces further transcription of endoplasmic reticulum stress response genes. genes 52, 63, 65 ( Figure 2) . Prolonged or extreme ER stress induces the expression of the transcription factor CHOP, causing synthesis of proapoptotic proteins and triggering ER-mediated cell death. 64 Given the key roles of the SR in cardiomyocytes in calcium handling, as well as in integrating calcium cycling and metabolism via its dynamic association with the mitochondria, 66 the ER stress response machinery has an important impact in heart physiopathology, which merits further investigation.
Molecular chaperones and protein quality triage
Degradation of misfolded proteins is instrumental to the constant turnover of sarcomere proteins, required for correct contractile function and regulation of the cardiac mass. 67 Chaperone proteins can direct misfolded proteins to degradation via the ubiquitin-proteasome system or the autophagic process ( Figure 3 ). In the first case, ubiquitin ligase enzymes, in association with chaperones, label misfolded proteins with multiple ubiquitin molecules. Ubiquitin serves as a recognition signal that directs proteins to the proteasome, a large multi-subunit enzyme complex with protease activity. C-terminal of HSP70-interacting protein (CHIP) is a ubiquitin ligase highly expressed in the heart 68 that, in co-operation with Hsp70 and Bag1, controls degradation of myosin and other sarcomeric proteins, 14, 69 targeting them to the proteasome 70 ( Figure 3) . Notably, in the absence of CHIP, ischaemic damage leads to an increased infarct size 13 ( Table 1) . When misfolded proteins accumulate, large protein aggregates form, which also activates the Figure 3 Molecular chaperones control unfolded protein degradation. The chaperone machinery plays an active role in proteostasis by directing misfolded proteins to degradation via the ubiquitin-proteasome or the autophagy pathways. Two co-chaperone molecules, Bag1 and Bag3, function by directing damaged proteins to either the proteasome or the autophagosome systems. Bag1 co-operates with Hsp70 and CHIP, a ubiquitin ligase highly expressed in the heart, for ubiquitinating unfolded substrates and targeting them to the proteasome. In conditions of proteasome overload, unfolded proteins can form large aggregates, which are directed to the autophagy clearance pathway in a process known as chaperone-assisted selective authophagy (CASA) by Bag3, in association with Hsc70, the small chaperone HspB8 and the p62 protein that directs the cargo to the autophagosomal membrane.
autophagy pathway of degradation. Damaged cellular organelles and misfolded protein aggregates are surrounded by double membrane autophagic vacuoles that fuse with lysosomes, allowing their contents to be degraded by lysosomal hydrolases. 14, 71 Autophagy is associated with a number of cardiac diseases, including heart failure and ischaemic heart disease. 72 The co-chaperone Bag3 and the sHsps HspB8 are important players in autophagic clearance in the heart, and are involved in a process known as chaperone-assisted selective autophagy 14, 73 ( Figure 3) . Interestingly, Bag3 mutations cause dilated cardiomyopathy in humans and in genetically modified mouse models, 16, 17 further underlining the key role of protein triage mechanisms in heart function.
Molecular chaperones control signal transduction
Chaperones also play a crucial role in signal transduction, as they are able to control protein folding during the conformational switches occurring in activation or deactivation of signalling proteins. An additional mechanism is represented by the ability of chaperones to promote the formation of supramolecular protein complexes and to stabilize the dynamic interaction of the different signalling components. Most Hsp90 clients are signal transduction proteins, 74, 75 such as Src, Raf, Akt, PI3K, Pdk1, and eNos. 76 -78 Hsp90 interaction with kinases involves the co-chaperone protein Cdc37. Genetic studies in Drosophila have shown that both Hsp90 and Cdc37 are essential for facilitating Raf1 kinase activation by up-stream regulatory molecules. Exposure to the Hsp90 inhibitor geldanamycin dissociates Raf1-Hsp90 complexes, resulting in Raf1 degradation. Indeed, most signalling proteins undergo degradation upon pharmacological inhibition of Hsp90, highlighting the crucial importance of chaperone function in signal transduction. 58, 79 An additional example of Hsp90 function in signal transduction is represented by its role in VEGF-dependent eNos activation in endothelial cells. 80 VEGF stimulation leads to the disruption of the caveolin-eNos complex and promotes the association between eNos and Hsp90. eNos-bound Hsp90 then recruits activated Akt to the complex, which in turn phosphorylates eNos on its S1177 residue. 80 In addition to Hsp90, sHsps and co-chaperones, such as HspB6, 32 HspB8, 42 melusin, 81 and Bag3, 15 regulate signalling pathways that control cardiomyocyte survival and calcium cycling ( Table 1) , with a strong impact on cardiac function. In particular, HspB6 can form a molecular complex with Akt, promoting its activity and the pro-survival pathway via Bad phosphorylation and caspase-3 inhibition. 36 Moreover, HspB6 regulates Ca 2+ cycling, improving diastolic and systolic functions, via binding and inhibition of protein phosphatase 1 (PP1) 82 ( Figure 4 ). This leads to increased phospholamban phosphorylation and the subsequent activation of the SR SERCA2a calcium pump. 82 This function requires HspB6 Ser16 phosphorylation by PKA 83 in response to b-adrenergic stimuli, 84 as discussed below in Section 5. Melusin, a sHsp that promotes cardiomyocyte survival in stress conditions and compensatory hypertrophy, is an additional example of how molecular chaperones can regulate signalling pathways by controlling the assembly and spatial organization of signalling complexes. 44, 45, 81 Furthermore, in association with Hsp90, 85 melusin promotes the organization of a signalosome complex that regulates both Erk1/2 and Akt signalling in response to different stresses. The signalosome complex includes the scaffold protein Iqgap-1 that binds to the three MAP kinases, c-Raf, Mek1/2, and Erk1/2 86 and the focal adhesion kinase (Fak), required for Erk1/2 activation 86 ( Figure 4) . Melusin can also bind to the regulatory subunit p85 of class IA PI3Ks 87 and to Akt, 88 which results in activation of an important pro-survival pathway.
Molecular chaperones can buffer genetic mutations
Genetic mutations often induce protein misfolding and chaperone proteins, by binding to mutated polypeptides, can favour their re-folding and restore their function. In this context, it has been hypothesized that chaperones can buffer deleterious mutations, playing a crucial role in the evolution of new protein functions and phenotypic traits. 56,89 -92 Indeed, when mutant forms of different enzymes are co-expressed with a high level of molecular chaperones, the number of mutant enzymes retaining catalytic activity strongly increases, demonstrating the ability of chaperones to buffer the phenotypic effect of a wide range of mutations. 93 In support of this notion, overexpression of HspB5/aB-crystallin effectively prevents formation of protein aggregates of mutated desmin in cultured cells. 94 Since mutated desmin protein aggregates cause important genetic cardiomyopathies in humans, 95 it can be hypothesized that overexpression of chaperone proteins can counteract heart diseases caused by mutations of cytoskeletal and sarcomeric proteins. An additional level by which chaperone proteins can impact on genetic mutations is suggested by the ability of Hsp90 to prevent transposon-induced genetic variations, 96 therefore acting as a genome guardian. Transposons are non-coding DNA regions that can change their position within the genome, by 'copy and paste' or 'cut and paste' mechanisms, thus creating or reversing mutations. Using the Drosophila model, it has been recently shown that pharmacological or genetic inhibition of Hsp90 activity causes reduced biogenesis of piRNA, a class of small RNAs involved in transposon silencing. Accordingly, if Hsp90 cannot fulfil its required chaperone functions, for example, under severe stress conditions, transposon activity is increased, and de novo genetic variations can be generated by transposon-mediated 'canonical' mutagenesis. 96 Given that severe and chronic stress conditions are common features of heart pathologies, it is tempting to speculate that genomic instability can play a role in cardiac disease and maladaptive remodelling. This hypothesis needs to be experimentally assessed.
Impact of molecular chaperones in cardiac diseases
The role of chaperone molecules has mainly been investigated in three pathological cardiac conditions, namely I/R injury after myocardial infarction; long-term maladaptive remodelling of the left ventricle (LV) in response to pressure overload or other pathological noxia, and conduction deficiencies causing arrhythmia. These aspects will be discussed separately.
Molecular chaperones strongly protect against I/R injury
During myocardial infarction, the lack of oxygen and nutrients induces severe tissue damage. However, during coronary re-opening, by thrombolysis or primary percutaneous coronary intervention, additional tissue damage occurs, a phenomenon known as I/R injury. Specifically, re-oxygenation of ischaemic myocardium generates a rapid burst of reactive oxygen species causing cell death and consequent further myocardial injury. Oxidative stress causes major sarcolemmal and SR cardioprotective activity of molecular chaperones is based mainly on their ability to promote cardiomyocyte survival even though this is achieved via different mechanisms. HspB5 is promoting correct folding of desmin and its assembly in the intermediate filaments of the cytoskeleton. HspB5 also binds to the N2B region of the sarcomeric protein titin, preventing its unfolding during overstretching and cardiomyocyte stiffening. Genetic mutations of HspB5 cause cardiomyopathy in humans due to accumulation of misfolded desmin protein aggregates. HspB6 promotes cardiomyocyte survival by activating the AKT, as well as by inhibiting the ASK-JNK/p38 pathways. HspB6 in addition, by interacting with phosphatase PP1, increases phospholamban phosphorylation, which in turn leads to increased SERCA2 calcium pump activity and improves cardiomyocyte contractility. HspB8 regulates bone morphogenic protein receptor (BMPRII) expression and signalling by promoting TAK1/AKT downstream activation. HspB8 also co-operates with BAG3 and Hsc70 in routing misfolded protein aggregates to autophagic vesicles, thus, reducing proteotoxicity. Melusin promotes cardiomyocyte survival and hypertrophy via ERK1/2 signalling by organizing a signalosome complex involving the chaperone Hsp90, the scaffold protein IQGAP1, and the kinases FAK, RAF MEK, and ERK.
Molecular chaperone networks for treating heart disease membrane damage, leading to an increase in intracellular Ca 2+ levels with resulting cardiomyocyte hyper-contracture, mitochondrial damage, and cell death. 97 Chaperone protein expression is rapidly induced after ischaemic shock 7 and many studies have implicated these molecules as mediators of myocardial protection in experimental I/R injury models ( Table 1) . Preconditioning manoeuvres, consisting of rapid and repeated ischaemic events, have been shown to result in an increased expression of Hsp70, leading to subsequent protection from prolonged myocardial injury. 8, 9, 98 Indeed, cardioprotective effects of Hsp70 have been demonstrated in isolated adult cardiomyocytes, 99 as well as in transgenic hearts after global or regional ischaemia. 10, 11 Hsp90 also plays an important role in reducing myocardial dysfunction upon I/R. The protective function of Hsp90 is based on its ability to regulate both the kinase Akt and the phosphatase calcineurin, leading to eNOS serine 1177 phosphorylation and threonine 495 dephosphorylation, respectively. HspB2 and HspB5, also known, respectively, as Hsp27 and aB-crystallin, 100 are major sHsps expressed in the heart. Mice lacking both genes have reduced contractility after I/R challenge, with parallel increases in necrosis and apoptosis, compared with wild-type mice. Although these chaperones are not required for cardiac development and basal function, they play a key role in antioxidative mechanisms during I/R injury. 26 Moreover, gain-of-function experiments have demonstrated that just a minimal (two-to three-fold) increase in HspB2 expression protects dog cardiomyocytes against I/R injury. 25 In addition, transgenic mice overexpressing HspB5 develop less oxidative stress, have a decreased infarct size, and are protected from cardiomyocyte apoptosis in response to I/R. 27 During severe ischaemia, HspB5 associates with sarcomeric structures, and this event correlates with increased HspB5 phosphorylation. 101 In addition, HspB5 specifically binds to the N2B region of the sarcomeric protein titin, preventing its unfolding during overstretching. 102 Notably, specific HspB5 mutations affecting titin binding are associated with cardiomyopathy in humans 29 (see below).
Among the small molecular chaperones, HspB6, also known as Hsp20, 100 has been extensively studied for its cardioprotective activity. 32, 33 Forced expression of HspB6 in hearts of transgenic mice reduces the extent of infarction and apoptotic cell death following ischaemic insult. 103 The anti-apoptotic effect of HspB6 can be explained by its ability to form a molecular complex with Akt, sustaining its activity, and leading to phosphorylation of the pro-apoptotic protein BAD and reduced amount of cleaved caspase-3 36 ( Figure 4) . In addition to its prosurvival function, HspB6 overexpression also improves cardiac contractility after I/R injury 103 as a result of increased Ca 2+ cycling and SR Ca 2+ load. In fact, HspB6 can bind and inhibit PP1, which plays a role in dephosphorylation of phospholamban, resulting in a specific increase in phospholamban phosphorylation, relieving its inhibition on the SR SERCA2a calcium pump 82 ( Figure 4) . The protective ability of HspB6 against I/R injury depends on its Ser16 phosphorylation by PKA; 83 mice that overexpress the HspB6 S16A phospho-null mutant exhibit reduced recovery of contractile function in response to ischaemia/reperfusion, and display increased necrosis, apoptosis, and heart damage. 34 Interestingly, a naturally occurring mutant of HspB6 at position 20 (P20L substitution) is associated with markedly reduced Ser16 phosphorylation of HspB6, and this correlates with the abrogation of the cardioprotective effects of HspB6. 39 HspB6 expression in the heart increases in response to I/R injury, which involves the down-regulation of miRNA320. In fact, miRNA320, the only miRNA which rapidly decreases in expression after reperfusion, targets HspB6 transcripts, causing down-regulation of HspB6 protein in cardiomyocytes. 35 Notably, in vivo miRNA320 knockdown decreases cardiac infarct size, therefore, representing a potential target for increasing HspB6 expression for therapeutic approaches.
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HspB8 (also known as Hsp22 100 ) has an important cardioprotective function. HspB8 levels in the heart increase by three-fold after ischaemia/reperfusion, and transgenic mice that overexpress HspB8 in the myocardium are protected from I/R injury. 40 The cardioprotective effect of HspB8 appears to be mediated through bone morphogenic protein (BMP) signalling. Indeed, HspB8 expression leads to upregulation of the Alk3 and bone morphogenic protein receptor (BMPR)-II receptors and their ligand BMP4. Moreover, HspB8 induces increased association of Alk3 with BMPR-II, promoting their interaction with TAK1, an intracellular kinase that regulates BMP-dependent PI3K/ Akt signalling and cardiomyocyte survival 41 ( Figure 4 ).
As mentioned above, efficient clearance of damaged proteins is crucially important when protein refolding fails. The ubiquitination of unfolded proteins and their targeting to the proteasome represents a major degradation pathway. Indeed, mice deficient in CHIP, a co-chaperone with ubiquitin ligase activity, show a 50% greater infarct area compared with wild-type mice, when challenged with I/R injury, 13 the accumulation of damaged proteins being the likely cause of cardiomyocyte death.
ER stress also deeply impacts on the response of the heart to ischaemia. Indeed, hypoxia induces activation of the ER 'unfolded protein response' by increasing splicing of XBP1 mRNA and Grp78 protein levels. 48 The functional relevance of these molecules in cardioprotection is shown by the fact that dominant-negative XBP1 augments hypoxia/reoxygenation-induced apoptosis, 48 and silencing of Grp78 attenuates the preconditioning-mediated resistance to ischaemia. 49 The ATF6 component of the ER stress response also has an important cardioprotective function. This has been demonstrated by inducible activation of ATF6 in the heart, 53 which causes an increased expression of ER-resident chaperones Grp78 and Grp94, allowing better functional recovery from ex vivo I/R, as well as significantly reduced necrosis and apoptosis. Conversely, treatment of mice with the ATF6 inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride further reduces cardiac function and increases the mortality rate following myocardial infarction. 52 The ER PDI is up-regulated by three-fold in the viable peri-infarct myocardial region of human heart samples, and has a clear cardioprotective effect. 51 In fact, PDI overexpression in the mouse heart results in reduced infarct size, cardiomyocyte apoptosis, and left ventricular dilation. 51 
Chaperones can prevent maladaptive remodelling of the LV and delay heart failure
The heart is able to modify its shape, as well as its volume, in response to a need for altered force production. Intense exercise or pathological stimuli, such as hypertension, result in increasing mechanical stretch on myocardial walls, which is sensed by cardiomyocytes, leading to activation of signal transduction pathways that regulate gene expression and drive compensatory hypertrophic reactions. Sarcomeric protein synthesis increases due to these stimuli, resulting in the addition of new sarcomeres, in parallel with the existing contractile units, to counteract the increased workload. Indeed, an increase in chaperone expression occurs during hypertrophy when the intense protein synthesis requires potentiating the folding machinery to ensure efficient protein processing and assembly into the sarcomeric structures. 56, 104 When this system becomes overwhelmed, misfolded proteins accumulate, causing cellular damage and development of cardiac dysfunction, which can drive cardiomyocyte hypertrophy towards maladaptive remodelling. 1 Several chaperone proteins have been shown to have a cardioprotective role against pathological evolution ( Figure 4) . Moreover, an additional mutation (R157H) affects the interaction of HspB5 with titin, and is associated with dilated cardiomyopathy. 29 HspB5 expression is increased in response to transverse aortic constriction, 28 indicating that this molecule is up-regulated in response to pressure overload stress. 1 Transgenic mice that overexpress HspB5 display attenuated heart hypertrophy in response to pressure overload, without signs of LV functional impairment, consistent with the finding that HspB5 overexpression in cultured cardiomyocytes blunts hypertrophy induced by norepinephrine, phenylephrine, or isoproterenol. 28 Conversely, HspB5 null mice show an accelerated transition towards heart failure in response to pressure overload induced by aortic banding.
1,28
A private heterozygous HspB6 point mutation (P20L) was detected in one patient affected by dilated cardiomyopathy and three individuals without heart disease, suggesting that HspB6 acts as a modifier, favouring the development of dilated cardiomyopathy, likely in association with additional mutations or risk factors. 39 Interestingly, the P20L HspB6 mutant is unable to protect against apoptosis, as assessed by cardiomyocyte transfection. Cardiac overexpression of wild-type HspB6 protects the heart against maladaptive remodelling induced by prolonged isoproterenol infusion, attenuating the cardiac hypertrophic response, markedly reducing interstitial fibrosis, and decreasing apoptosis. 33, 37 These beneficial effects were associated with attenuation of the ASK1-JNK/p38 signalling cascade triggered by isoproterenol 37 ( Figure 4) . The HspB6 transgenic model also protects against cardiomyopathy induced by chronic doxorubicin treatment due to the ability of HspB6 to sustain Akt phosphorylation. 36 In addition, in order to protect cardiomyocytes from apoptosis, HspB6 also improves LV contractility, most likely via the ability of this sHsp protein to modulate Ca 2+ cycling via phospholamban phosphorylation (Figure 4) , as discussed in the previous sections. 82 Interestingly, pro-survival and calcium handling functions are apparently independent and involve different domains of the HspB6 protein.
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HspB7 is also known as cardiovascular Hsp (cvHsp) as it is expressed at high levels in cardiac and skeletal muscle, 59 and several genome-wide association studies have identified HspB7 as a cardiomyopathyassociated gene. 18 -21 Experimental evidence indicates that HspB7, rather than promoting protein refolding, plays a critical role in preventing protein aggregation. 62 The in vivo function of HspB7 in the heart has not yet been investigated, but a protective role in an in vitro model of pacing-induced cardiac remodelling has been reported. 38 Overexpression of HspB8 (also known as Hsp22 100 ) in cultured cardiomyocytes and the intact mouse heart results in the development of concentric hypertrophy with preserved contractile function, characterized by the re-expression of the foetal gene programme. 43 HspB8 knockout mice have a normal cardiac phenotype in basal conditions but, upon exposure to pressure overload, they develop impaired hypertrophy and contractile function, with increased ventricular dilation, accumulation of interstitial collagen, faster transition into heart failure, and increased mortality. 42 Silencing and overexpression experiments in isolated neonatal rat cardiomyocytes showed that HspB8 activates STAT3 via production of interleukin-6. 42 In addition to its transcriptional function, STAT3 translocates to the mitochondria, where it increases oxidative phosphorylation. Both mitochondrial STAT3 translocation and respiration are significantly decreased in HspB8 knockout mice. 42 Thus, HspB8 represents an activator of both nuclear and mitochondrial functions of STAT3, and its deletion, in the context of pressure overload in vivo, accelerates the transition into heart failure and increases mortality. HspB8 is known to form a complex with Bag3, a Bcl2-associated athanogene domain-containing protein, and to regulate the degradation of misfolded and aggregated proteins via macro-autophagy. 73, 108 In association with HspB8, Bag3 induces phosphorylation of the a-subunit of the translation initiator factor eIF2 that, in turn, causes protein synthesis inhibition and stimulates autophagy. The mechanism by which the Bag3-HspB8 complex induces eIF2 phosphorylation is not completely understood, and is independent of Hsp70. 109, 110 In muscle, Bag3 collaborates with Hsc70 in maintaining myofibril integrity under mechanical stress. 111 Moreover, together with HspB8 and Hsc70, Bag3 mediates chaperoneassisted autophagy of filamin, a cytoskeletal protein that undergoes continuous unfolding and refolding cycles during muscle contraction 14 ( Figure 4) . Interestingly, a number of Bag3 gene mutations were discovered in cases of adult-onset dilated cardiomyopathy. 16, 17, 22, 23 In addition, genome-wide and candidate gene-association studies have indicated Bag3 as being a cardiomyopathy-associated gene. 17 -21 Importantly, Bag3 knockdown in a zebrafish model causes heart failure that resembles human dilated cardiomyopathy, 17 and Bag3 null mice develop a severe form of cardiomyopathy and skeletal myopathy, 15 demonstrating a key role of this co-chaperone in the heart and muscle function (see also below). Melusin is a non-canonical chaperone protein selectively expressed in skeletal muscle and the heart. The C-terminal portion of melusin contains a CS domain homologous to the a-crystallin-p23-like domain that characterizes the family of sHsp proteins. Melusin is endowed with chaperone activity and directly binds to Hsp90, thus behaving as an Hsp90 co-chaperone. 85 Melusin expression in the heart is up-regulated in response to pressure overload 45 and ischaemic injury. 112 While the absence of melusin does not impair cardiac function in basal conditions, melusin-null mice fail to develop compensatory cardiomyocyte hypertrophy, and undergo accelerated LV dilation and failure, when subjected to chronic pressure overload. 44 Moreover, melusin overexpression in the heart results in sustained compensatory hypertrophy and prevents the transition towards heart failure, upon chronic pressure overload. 45 The protective effect of melusin occurs via increased cardiomyocyte hypertrophy and survival, reduced inflammation, and fibrosis. 45, 86, 112 At the molecular level, melusin is involved in the organization of a signalosome complex controlling Erk1/2 and Akt pathway activation in cardiomyocytes. 44, 45 Melusin, in fact, binds to the scaffold protein Iqgap-1 that, in turn, interacts with c-Raf, Mek1/2, and Erk1/2, allowing correct sequential phosphorylation of these three MAP kinases 86 ( Figure 4 ). An additional component recruited in the melusin-Iqgap-1 signalosome is Fak. Both, Fak and Iqgap-1 are required for melusin-dependent Erk1/2 activation, which leads to cardiomyocyte hypertrophy and protection from apoptosis. 86, 88 In addition, melusin also modulates Akt signalling, 44, 45 likely by forming a complex with the regulatory subunit p85 of class IA PI3Ks. 87 It therefore can be hypothesized that melusin, by forming a large signalosome complex, functions as a molecular hub integrating Akt and Erk pathways and driving a compensatory hypertrophy response. Two missense genetic Molecular chaperone networks for treating heart disease variations, partially associated with either hypertrophic or dilated cardiomyopathy, have been reported in two independent studies involving a total of 911 cardiopathic patients. 46, 47 The mitochondrial chaperone Hsp40, also known as Dnaja3, 100 has an important function in preventing dilated cardiomyopathy. 12 Indeed, mice deficient in Hsp40 develop dilated cardiomyopathy and die before 10 weeks of age. Hsp40 is crucial for mitochondrial biogenesis through its chaperone activity on the a-subunit of mitochondrial DNA polymerase gamma (Polga). 12 Progressive respiratory chain deficiency and decreased copy number of mitochondrial DNA are both evident in cardiomyocytes lacking Hsp40, highlighting the key role of this chaperone.
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The ER stress response is also activated in patients with heart failure, as shown by an increased expression of spliced XBP1 mRNA, Grp78, and CHOP. 63 CHOP is a pro-apoptotic transcription factor induced by prolonged ER stress, and inactivation of this gene in mice leads to reduced cardiac hypertrophy, fibrosis, apoptosis and improved LV contractility upon pressure overload. 50 Therefore, CHOP, by initiating apoptotic cell death, contributes to the development of maladaptive hypertrophy and heart failure induced by pressure overload. ATF6 activation, on the other hand, has an important role in cardioprotection in a pressure overload-induced heart failure model, and a novel mechanism of activation involving thrombospondin-4 has been demonstrated. 54 Thrombospondins are extracellular matrix proteins which transit through the ER during their synthesis, and their up-regulation is known to have a cardioprotective role. 113 Thrombospondin-4 up-regulation after aortic banding leads to activation of an adaptive stress response during its transition through the ER. This activation involves binding of thrombospondin-4 to the ER luminal domain of ATF6, leading to its processing and shuttling to the nucleus, where it promotes transcription of ER stress response genes. 54 This is an interesting example of how cardioprotective mechanisms can be activated by intracellular proteins during stress conditions, via the ER stress response machinery.
Chaperones can limit cardiac arrhythmia and atrial fibrillation
Cardiac arrhythmias are a common and, sometimes, lethal manifestation of either acquired or inherited diseases, caused by abnormalities in surface membrane ion channel function. Molecular chaperones can have a significant impact on arrhythmias by controlling channel protein maturation and transition to the plasma membrane. 5 The HERG potassium channel is a major regulator of action potentials in the heart, and when mutated causes different forms of long QT syndrome. The HERG channel is a membrane protein synthesized in the ER and transferred to the plasma membrane through the Golgi apparatus. 5 Correct ion conductance requires efficient delivery of the HERG channel to the plasma membrane by means of this secretory pathway. Indeed, Hsp70 and Hsp90 can form a complex with the immature HERG protein 6 in the ER, and inhibition of Hsp90 with geldanamycin prevents the maturation of HERG channels by the Golgi and secretory vesicles, promoting their degradation via the ubiquitin pathway, and reducing the number of molecules that reach the plasma membrane. 5, 6 Thus, chaperone proteins, by interacting with the cytosolic domain of immature HERG proteins, facilitate their transition and maturation through the secretory pathway, assuring efficient cell surface localization. Atrial fibrillation is a common form of cardiac arrhythmia characterized by rapid and irregular electrical discharges produced in the atria that alter the sinus rhythm. 114, 115 Atrial fibrillation induces tissue remodelling that favours the induction and maintenance of this electrical disorder. The irregular electrical firing during atrial fibrillation causes excess Ca 2+ entry via the L-type Ca 2+ channel into the myocytes, causing calpain-mediated myofibril damage degradation and myocyte death, further enhancing contractile dysfunction. 116 Since conventional anti-arrhythmic drugs often fail to provide effective sinus-rhythm maintenance, there is a great interest in innovative therapeutic approaches to correct this problem. 117 Chaperone proteins can play an important role in this context by different means (Table 1) . Indeed, induction of the expression of small Hsps has been shown to protect against atrial fibrillation both in a HL-1 atrial myocyte in vitro model of atrial tachycardia remodelling, 118 as well as in an in vivo model of tachypacing-induced atrial fibrillation in dogs. 24 In particular, there is an increased expression of HspB1 (also referred to as Hsp25/27/28 100 ) in tachypaced cardiomyocytes and phosphorylation of HspB1 prevents tachypacing-induced remodelling. 24 Overexpression of HspB1 was shown to provide protection against pacing-induced cardiomyocyte damage, through myofibrillar preservation from proteolysis by calpain. 118, 119 HspB6, HspB7, and HspB8 also protect against tachycardia-induced atrial cardiomyocyte remodelling, but in an HspB1-independent manner, 38 indicating that different sHsps can independently function as protective agents.
Molecular chaperones as drug targets for cardiac diseases
The broad cardioprotective function discussed above strongly supports the notion that strategies aimed at enhancing Hsp expression can be an important approach for preserving cardiac function in a variety of pathological conditions. Such strategies can be achieved in a number of ways including the use of small molecules capable of inducing Hsp expression or activation by phosphorylation.
Chaperones are induced at the transcriptional level in response to different stress conditions. Hsf1 is the best characterized transcription factor that binds to heat shock response elements in the promoter regions of stress-induced genes. 120 In unstressed conditions, Hsf1 binds Hsp90 and is consequently retained in an inactive state in the cytoplasm. Different stress conditions such as heat shock or accumulation of misfolded proteins, lead to dissociation of Hsp90 from Hsf1, allowing its translocation to the nucleus where it up-regulates transcription of chaperone genes. Physical exercise results in hyperthermia and subsequent elevation of myocardial Hsp70, Hsp90, and HspB5. 121 Indeed, regular endurance exercise protects the heart against I/R and infarction. 122 The role of Hsps in exercise-induced cardioprotection is, however, debated since exercise under conditions that prevent a raise in body temperature lead to cardioprotection, even in the absence of increased Hsp72 expression, 123 implying that Hsp72 induction might not represent the only mechanism of exercise-induced cardioprotection. A number of drugs are known to boost Hsp expression, including geranylgeranylacetone, arimoclomol, celastrol and statins 124 -129 ( Table 2) .
Most of these molecules induce Hsf1 expression, and consequently enhance transcription of several molecular chaperone genes. In several cases, Hsf1 induction is due to partial toxicity of the drug that functions as a potent stress response inducer. 125, 137 Geranylgeranylacetone is a cyclic polyisoprenoid that induces the expression of Hsf1 and Hsp70 mRNA, and is used in human patients for gastric ulcer treatment (NCT01190657, NCT01397448). At the pre-clinical level, geranylgeranylacetone has been shown to have an important cardioprotective function in a dog model of atrial fibrillation, 24, 133 as well as in pre-clinical models of desmin-related cardiomyopathy 132 and I/R 130,131 ( Table 2) .
Arimoclomol and celastrol have been shown to markedly improve muscle function and motoneuron survival in a mouse model of amyotrophic lateral sclerosis 134, 135 and arimoclomol is currently in phase II/ III clinical trials for treatment of human amyotrophic lateral sclerosis patients (NCT00706147) ( Table 2) . However, the therapeutic potential of arimoclomol and celastrol in cardiac diseases still needs to be assessed. Statins, popular drugs widely used to decrease cholesterol synthesis, have many additional activities including increasing Hsp expression. In particular, simvastatin and lovastatin induce HspB1, as well as Hsp70 and Hsp90, in a cell type-dependent manner in vitro and in vivo. 127 -129 Short-term simvastatin therapy appears to improve cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy, even though the mechanism of action has not yet been investigated 136 ( Table 2) . However, the reported side-effect of statins in inducing myopathies, possibly via inhibition of the synthesis of coenzyme Q10, and consequent mitochondrial damage, has questioned the possible therapeutic function of statins in cardiac diseases. 138 An additional possible approach for regulating sHsp function is to control their phosphorylation. As mentioned above, the small heat shock protein HspB6 is phosphorylated on Ser16 by PKA, and this posttranslational modification is required for its chaperone function and cardioprotective activity. 34 In unstressed conditions, HspB6 complexes with phosphodiesterase PDE4, increasing cAMP hydrolysis, which inactivates PKA and maintains HspB6 in an unphosphorylated, inactive state. 84 Peptides capable of specifically inhibiting the HspB6-PDE4 interaction can promote PKA activation and HspB6 phosphorylation on Ser16, suggesting an important and highly selective mechanism for triggering HspB6 cardioprotective effects. 84 Most small Hsps, including HspB1, HspB5, HspB8, and HspB10, 59 can be phosphorylated by different kinases such as the p44/p42 MAPK, 139 the MAPKAPK-2 and -3, 140 and the cGMP-dependent protein kinase. 141, 142 Phosphorylation can favour formation of small oligomers, while de-phosphorylation results in a shift towards large oligomer formation, 143 indicating that oligomerization is important for chaperone activity. 59 Moreover, phosphorylation of sHsps can affect their subcellular localization, as demonstrated by nuclear localization of HspB1. 59, 144 Thus, controlling sHsp phosphorylation can represent a strategy for activating and/or regulating selected chaperone molecules. Gene therapy can also be considered as a possible option to increase Hsp levels and function. In particular, adeno-associated viral vectors, which have been successfully utilized in clinical trials for the treatment of cardiomyopathy with SERCA2 overexpresison, 145 are currently the most effective in vivo delivery system.
Concluding remarks
Molecular chaperones are members of a large family of proteins that control protein folding and degradation, thus allowing a physiological control of proteostasis. Loss of regulation of the physiological balance between protein synthesis, folding, and degradation results in accumulation of misfolded proteins, causing several pathologies, including heart diseases such as ischaemia, maladaptive remodelling in heart failure, and arrhythmias. The considerable body of data discussed in this manuscript demonstrates that increasing molecular chaperone expression Improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy provides a major cardioprotective function in several experimental in vivo animal models, strongly designating chaperones as important innovative drug targets. Indeed, small molecules capable of increasing chaperone expression are currently being developed and used in clinical trials for the treatment of neurodegenerative diseases. Novel strategies to increase chaperone function and expression therefore represents a crucial approach for developing drugs of broad applicability for most common cardiac diseases.
